Deep learning accurately predicts estrogen receptor status in breast cancer metabolomics data

Abstract

Metabolomics holds the promise as a new technology to diagnose highly heterogeneous diseases. Conventionally, metabolomics data analysis for diagnosis is done using various statistical and machine learning based classification methods. However, it remains unknown if deep neural network, a class of increasingly popular machine learning methods, is suitable to classify metabolomics data. Here we use a cohort of 271 breast cancer tissues, 204 positive estrogen receptor (ER+), and 67 negative estrogen receptor (ER−) to test the accuracies of feedforward networks, a deep learning (DL) framework, as well as six widely used machine learning models, namely random forest (RF), support vector machines (SVM), recursive partitioning and regression trees (RPART), linear discriminant analysis (LDA), prediction analysis for microarrays (PAM), and generalized boosted models (GBM). DL framework has the highest area under the curve (AUC) of 0.93 in classifying ER+/ER− patients, compared to the other six machine learning algorithms. Furthermore, the biological interpretation of the first hidden layer reveals eight commonly enriched significant metabolomics pathways (adjusted P-value <0.05) that cannot be discovered by other machine learning methods. Among them, protein digestion and absorption and ATP-binding cassette (ABC) transporters pathways are also confirmed in integrated analysis between metabolomics and gene expression data in these samples. In summary, deep learning method shows advantages for metabolomics based breast cancer ER status classification, with both the highest prediction accuracy (AUC = 0.93) and better revelation of disease biology. We encourage the adoption of feed-forward networks based deep learning method in the metabolomics research community for classification.

DeepImpute: an accurate, fast and scalable deep neural network method to impute single-cell RNA-Seq data

“…DeepImpute is short for "Deep neural network Imputation". As reflected by the name, it belongs to the class of deep neural-network models (Ching, Zhu, et al , 2018;Alakwaa et al , 2018;Chaudhary et al , 2018) . Recent years, deep learning and related deep neural network algorithms have gained much interest in the biomedical field (Ching, Himmelstein, et al , 2018) , ranging from applications from extracting stable gene expression signa tures in large sets of public data (Tan et al , 2017) to stratify phenotypes (Beaulieu-Jones et al , 2016) or impute missing values (Beaulieu-Jones and Moore, 2017) using electronic health record (EHR) data.…”

A plasma metabolite panel as biomarkers for early primary breast cancer detection

“…A general problem with metabolic studies is that no standardized method for data analysis and processing exist. Currently, researchers mainly use various statistical and machine learning‐based classification methods or even deep learning methods, which makes comparing study results difficult. Sample processing and the usage of serum or plasma are also expected to influence study results .…”

Predicting molecular subtypes of breast cancer using pathological images by deep convolutional neural network from public dataset

“…In previous literatures, many models have been developed to predict or classify a wide range of diagnostic or therapeutic targets of breast cancer. in classifying ER+ and ER− patients [16].…”